Mood Emot 2022 Mar; 20(1): 1-7
Pharmacogenetics in Psychotropic Drugs
Jung An Lee, MD1 , Jung Goo Lee, MD, PhD1,2,3
1Department of Psychiatry, Haeundae Paik Hospital, Inje University College of Medicine, 2Paik Institute for Clinical Research, Inje University, 3Department of Health Science and Technology, Graduate School, Inje University, Busan, Korea
Correspondence to: Jung Goo Lee, MD, PhD
Department of Psychiatry, Haeundae Paik Hospital, Inje University College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan 48108, Korea
TEL +82-51-890-6749 FAX +82-51-984-6709 E-mail ORCID
Received: March 8, 2022; Accepted: March 12, 2022; Published online: March 31, 2022.
© Korean Society for Affective Disorders. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pharmacogenetics is used in psychiatry to predict the effects and side effects of psychotropic drugs. As most mental disorders have complex causes and unpredictable outcomes, personalized treatment using pharmacogenomics would be a useful method. However, pharmacogenetic studies in psychiatry have yielded insignificant results thus far, making their clinical application extremely limited. Early testing, prediction of drug side effects, and drug compliance will be discussed as considerations for the effectiveness of the pharmacogenetic test in psychiatry. Although pharmacogenetic tests in psychiatry do not yet have high sensitivity and specificity, they may be useful in the future for predicting clinical prognosis or developing novel drug treatments. As a result, the authors summarized the current state and prospects of pharmacogenetics in psychiatry in this review.
Keywords: Pharmacogenetics; Psychopharmacology; Psychotropic drugs

  • Search

This Article